Description

RET-3W-GL3 (LY-3437943)

RET-3W-GL3 is an investigational triple receptor agonist peptide developed by EliLilly targeting GLP-1, GIP, and glucagon receptors. It is being studied primarily for obesity, type 2 diabetes, and related metabolic disorders. By simultaneously activating these pathways, RET-3W-GL3 aims to suppress appetite, enhance satiety, increase energy expenditure, and improve fat metabolism.

Key Benefits

Significant Weight Loss: Clinical trials have shown substantial body weight reductions, with up to 28.7% average weight loss (approximately 71 lbs / 32 kg) at 68 weeks with higher doses (9–12 mg) in Phase 3 studies. Many participants achieved 25–35%+ weight loss.
Improved Glycemic Control: Reduces HbA1c by 1.3% to 2.0%, making it a promising option for type 2 diabetes management.
Liver Fat Reduction: Demonstrates strong efficacy in reducing hepatic fat, with up to 86% relative reduction and over 85–93% of patients with MASLD (metabolic dysfunction-associated steatotic liver disease) reaching normal liver fat levels (<5%).
Cardiometabolic Improvements: Lowers triglycerides, LDL cholesterol, systolic blood pressure, and waist circumference.
Appetite Regulation: Potent suppression of hunger and reduction in overeating.
Additional Potential Indications: Currently under investigation for obstructive sleep apnea, knee osteoarthritis pain reduction, chronic low back pain, and other obesity-related complications.

Potential Side Effects

Common (usually mild to moderate and improve with time): Nausea, vomiting, diarrhea, constipation.
Other Notable: Increased heart rate (typically +6–7 bpm), skin tingling or dysesthesia.
Rare but Serious: Pancreatitis, gallbladder issues, severe gastrointestinal events, or cardiac arrhythmias. Immediate medical attention is required for severe symptoms.
Overall Safety: Generally well-tolerated in clinical trials with side effects similar to other incretin-based therapies, though potentially more pronounced GI effects due to triple agonism. Long-term safety data beyond 1–2 years is still being collected.

Note: RET-3W-GL3 is not FDA-approved and remains in Phase 3 clinical trials as of 2026. It is currently only available through clinical studies.

Peptide Combinations

Peptides it may pair well with:

Semaglutide or Tirzepatide (potential complementary effects on GLP-1 pathways for enhanced weight loss and metabolic outcomes — though formal combination studies are limited).

Peptides/Drugs to Avoid Combining:

Other strong glucagon receptor agonists or incretin-based therapies to minimize risk of additive side effects such as intensified GI issues, elevated heart rate, or hypoglycemia.

Research Disclaimer: This information is for educational and research purposes only. RET-3W-GL3 is an investigational compound. Consult qualified healthcare professionals before considering any experimental therapies. Lifestyle interventions (diet, exercise, adequate protein intake) remain essential when using any weight-management agents to help preserve muscle mass.

Would you like me to adjust the formatting (e.g., add sections, change tone, include references, or make it more concise) for your website?